Helicobacter pylori infection
Conditions
Interventions
The tetracycline group:Vonoprazan 20mg Bid po + tetracycline 500mg Tid po for 14 days
The minocycline group:Vonoprazan 20mg Bid po + minocycline 100mg Bid po for 14 days
The doxycycline group :Vonoprazan 20mg Bid po + doxycycline 100mg Bid po for 14 days
Sponsors
Lanzhou University Second Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 ~ 70 years old; 2. Confirmed Helicobacter pylori infection patients: 13C/14C urea breath test positive; 3. Patients with initial treatment of Helicobacter pylori and patients with previous radical treatment times < 2; 4. Subjects voluntarily join the study, sign the informed consent, and understand and agree to follow the study requirements.
Exclusion criteria
Exclusion criteria: 1. Any medication (PPI, potassium competitive acid blockers, H2 receptor antagonists H2RA, bismuth, antibiotics, etc.) taken in the past four weeks that may have affected the results of the study; 2. Patients whose previous helicobacter pylori radical treatment regimen was Venolazine duplex regimen or radical treatment regimen included tetracycline, minocycline, and doxycycline; 3. Patients who are known to be allergic to the drugs related to this study (venolazine, tetracycline, minocycline, doxycycline); 4. Women who are pregnant, breastfeeding or preparing for pregnancy; 5. Patients with malignant gastrointestinal tumors; 6. Patients with severe concomitant diseases (such as severe systemic diseases, liver and kidney dysfunction); 7. Patients who cannot describe adverse events due to various reasons such as old age, mental and psychological abnormalities.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance;Factors Affecting Eradication Rate; | — |
Countries
China
Contacts
Public ContactDekui Zhang
Lanzhou University Second Hospital
Outcome results
None listed